Загрузка...
Use of bevacizumab in recurrent glioblastoma
Glioblastoma (GBM) is the most common adult primary brain neoplasm. Despite advances in treatment, GBM continues to be associated with considerable morbidity and mortality as compared with other malignancies. Standard treatment for GBM results in survival of 12.9 months (95% CI: 12.3–13.7 months) wi...
Сохранить в:
| Опубликовано в: : | CNS Oncol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Future Medicine Ltd
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088330/ https://ncbi.nlm.nih.gov/pubmed/25906439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.8 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|